STOCKS TELEGRAPH

Tag: QNRX Stock

  • Quoin (QNRX) Shares Climb In Pre-Hour Trading On Encouraging Trial News

    Quoin (QNRX) Shares Climb In Pre-Hour Trading On Encouraging Trial News

    In pre-market trading, Quoin Pharmaceuticals, Ltd. (NASDAQ: QNRX) shares are seeing a significant increase, rising 54.25% to $9.81 as of the last check. The spike in QNRX stock followed announcement of favorable first findings from its ongoing Investigator Pediatric Peeling Skin Syndrome clinical study, which demonstrated the robust market reaction to promising clinical advancements.

    Positive First Results from the QRX003 Trial

    The study assesses Quoin’s experimental treatment for Peeling Skin Syndrome, a rare and incurable hereditary condition, QRX003. No adverse events have been documented, and the pediatric participant in the research has tolerated QRX003 well. A follow-up evaluation is planned for 24 weeks after the treatment has been ongoing, as a consequence of these encouraging first outcomes.

    Quoin’s study highlights the potential importance of Peeling Skin Syndrome in the medical world since it may be the first official clinical evaluation of the condition in young patients. After only 12 weeks of therapy, the patient notably showed a two-grade improvement in clinical evaluations, going from “severe” to “mild” in the Investigator’s Global Assessment (IGA) and from “moderate” to “clear” in the M-IASI index. These results are regarded as clinically significant and provide compelling early indications of QRX003’s potential for treatment.

    Better Life Quality and Plans for Study Expansion

    The validated Children’s Dermatology Life Quality Index (CDQLI) indicates that the patient has improved clinically and reported a higher quality of life. These results bolster confidence in QRX003’s safety and effectiveness profile and support the investigator’s choice to continue therapy.

    Inspired by these preliminary results, Quoin intends to expand the research by adding more pediatric participants from other nations. Through late-stage studies, the firm is also advancing QRX003 for Netherton Syndrome, another serious dermatological disorder.

    Getting a First-in-Class Approval Position

    As of right now, Peeling Skin Syndrome has no authorized therapies or ongoing clinical studies. This is a significant advancement in rare illness treatments and presents Quoin Pharmaceuticals (QNRX) with a rare chance to maybe obtain the first regulatory approval for a treatment aimed at this uncommon condition.

  • Quoin Pharma (QNRX) Aims For Top Spot in Rare Disease Market

    Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) is a pharma player with a focus on the rare disease segment. Its treatment for Netherton syndrome has been gaining interest among those with the condition, and management seems to be eyeing FDA approval within 2023. Its financing remains stellar, and all now rests on sound execution.

    Quoin Pharma Significant Updates

    In a recent earnings call, the CEO of Quoin Pharmaceuticals Ltd. (QNRX) reiterated Quoin’s strategic goal of transforming itself into a global company addressing rare diseases. In the final quarter of 2022, the company received funding of almost $17 million in an over-subscribed offering showing double upsize. Due to the cash injection, Quoin stands as having surpassed several inflection points to see its development pipeline continue without hitch. Moreover, the management remains confident about the recent trial it initiated on the QRX 003 candidate for addressing life-threatening conditions in Netherton patients. According to the FDA, 20 patients being tested with the candidate would be enough to attain regulatory approval, given the rare nature of the disease.

    Balance Sheet for QNRX Remains Solid

    Given the recent financing by public offering, QNRX sees a much stronger balance sheet than it did six months ago. At the end of the first half of 2022, its cash holdings stood at $2.7 million, whereas presently, this figure amounts to over $15 million. The company’s CFO has stated that it has received sufficient funding for it to push on development until 2024 when its pipeline would be in a far more mature stage.

    Conclusion

    QNRX faces the opportunity to shine with its funding complete, and a neat cash runway ahead of it. Its success now depends on its ability to execute, as the market will eagerly be awaiting a positive update from the company, especially in terms of its QRX 003 candidate.